2. Somatostatin and dopamine receptors

Tumori

Volumn 96, Issue 5, 2010, Pages 802-805

  Ferone, Diego ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; ANGIOPEPTIN; BIM 23A760; CYCLOPEPTIDE; DRUG DERIVATIVE; OCTREOTIDE; PASIREOTIDE;

ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; CANCER CELL; CELL GROWTH; CONFERENCE PAPER; CYTOTOXICITY; HUMAN; INTRACELLULAR SIGNALING; MOLECULAR INTERACTION; NEUROENDOCRINE TUMOR; TUMOR VOLUME; ANIMAL; ARTICLE; METABOLISM;

ANIMALS; DOPAMINE; HUMANS; NEUROENDOCRINE TUMORS; OCTREOTIDE; PEPTIDES, CYCLIC; RECEPTORS, DOPAMINE; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 78650507789     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089161009600531     Document Type: Conference Paper

References (15)

1. Ferone D, Gatto F, Arvigo M, Resmini E, Boschetti M, Teti C, Esposito D, Minuto F: The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology. J Mol Endocrinol, 42: 361-370, 2009.
2. Ferone D, de Herder WW, Pivonello R, Kros JM, van Koetsveld PM, de Jong Y, Minuto F, Colao A, Lamberts SWJ, Hofland LJ: Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. J Clin Endocrinol Metab, 93: 1412-1417, 2008.
3. Pivonello R, Ferone D, de Herder WW, Kros JM, Del Basso De Caro ML, Arvigo M, Annunziato L, Lombardi G, Colao A, Hofland LJ, Lamberts SWJ: Dopamine receptors expression and function in corticotroph pituitaty tumors. J Clin Endrocrinol Metab, 89: 2452-2462, 2004. (Pubitemid 38619889)
4. Pivonello R, Ferone D, Lamberts SWJ, Colao A: Cabergoline plus lanreotide for ectopic Cushing's Sindrome. N Engl J Med, 352: 2457-2458, 2005. (Pubitemid 40958451)
5. O'Toole D, Saveanu A, Couvelard A, Gunz G, Enjalbert A, Jaquet P, Ruszniewski P, Barlier A: The analysis if quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumors opens new therapeutic strategies. Eur J Endocrinol, 155: 849-857, 2006. (Pubitemid 46040624)
6. Srirajaskanthan R, Watkins J, Marelli L, Khan K, Caplin ME: Expression of somatostatin and dopamine 2 receptors in neuroendocrine tumors and the potential role for new biotherapies. Neuroendocrinol, 89: 308-314, 2009.
7. Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L, Culler MD, Moreau JP, Enjalbert A, Jaquet P: BIM-23244, a somatostatin receptor subtype 2- and 5- selective analog with enhanced efficacy in suppressing growth hormone (GH) from otcreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab, 86: 140-145, 2001.
8. Hofland LJ, van der Hoek J, van Koetsveld PM, de Herder WW, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, Feelders R, van der Lely A-J, Beckers A, Lamberts SWJ: The Novel Somatostatin Analog SOM230 Is a Potent Inhibitor of Hormone Release by Growth Hormone- and Prolactin-Secreting Pituitary Adenomas in Vitro. J Clin Endrocrinol Metab, 89: 1577-1585, 2004.
9. Jaquet P, Gunz G, Saveanu A, Dufour H, Taylor J, Dong J, Kim S, Moreau J-P, Enjalbert A, Culler MD: Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur J Endocrinol, 153: 135-141, 2005. (Pubitemid 41030524)
10. Florio T, Barbieri F, Spaziante R, Zona G, Hofland LJ, van Koetsveld PM, Feelders RA, Stalla GK, Theodoropoulou M, Culler MD, Dong J, Taylor JE, Moreau J-P, Saveanu A, Gunz G, Dufour H, Jaquet P: Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. Endrocr Relat Cancer, 15: 583-596, 2008.
11. Ferone D, Arvigo M, Semino C, Jaquet P, Saveanu A, Taylor JE, Moreau J-P, Culler MD, Albertelli M, Minuto F, Barreca A: Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation. Am J Physiol Endocrinol Metab, 289: E1044-1050, 2005.
12. Kidd M, Drozdov I, Joseph R, Pfragner R, Cullen M, Modlin I: Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines. Cancer, 113: 690-700, 2008.
13. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC & Patel YC: Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science, 288: 154-157, 2000. (Pubitemid 30203051)
14. Angers S, Salahpour A, Bouvier M: Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function. Annual Review of Pharmacology and Toxicology, 42: 409-435, 2002. (Pubitemid 34160532)
15. Pfeiffer M, Koch T, Schroder H, Klutzny M, Kirscht S, Kreienkamp HJ, Hollt V, and Schulz S: Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A). J Biol Chem 276: 14027-14036, 2001.